Cognition Therapeutics (CGTX) Amortization of Deferred Charges (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Amortization of Deferred Charges of $57000.0 for Q1 2026, up 5.56% year-over-year from $54000.0 in Q1 2025, and up 21.28% quarter-over-quarter from $47000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Amortization of Deferred Charges for 7 consecutive years, with $57000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 5.56% year-over-year to $57000.0; the TTM figure through Mar 2026 stood at $195000.0 (up 7.14% YoY), while the FY2025 annual figure was $192000.0, up 20.75% from the prior year.
- Amortization of Deferred Charges advanced to $57000.0 in Q1 2026 per CGTX's latest filing, from $47000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $57000.0 in Q1 2026 and bottomed at $31000.0 in Q1 2024.
- Historically, Amortization of Deferred Charges has averaged $42117.6 across 5 years, with a median of $40000.0 in 2023.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 333.33% — and 2024, when it declined 20.51%.
- Cognition Therapeutics' Amortization of Deferred Charges stood at $37000.0 in 2022, then rose by 5.41% to $39000.0 in 2023, then advanced by 12.82% to $44000.0 in 2024, then grew by 6.82% to $47000.0 in 2025, then gained by 21.28% to $57000.0 in 2026.
- Business Quant data shows CGTX's Amortization of Deferred Charges at $57000.0 in Q1 2026, $47000.0 in Q4 2025, and $46000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45,000.00 |
| Jun 30, 2026 | 45,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Mar 31, 2025 | 54,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Dec 31, 2024 | 44,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |